

# Matthew D Ringel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1759604/publications.pdf>

Version: 2024-02-01

170  
papers

14,059  
citations

23500

58  
h-index

20900

115  
g-index

176  
all docs

176  
docs citations

176  
times ranked

14219  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. <i>Cell</i> , 2014, 159, 676-690.	13.5	2,318
2	Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association. <i>Thyroid</i> , 2009, 19, 565-612.	2.4	1,247
3	BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6373-6379.	1.8	893
4	Phase II Trial of Sorafenib in Metastatic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1675-1684.	0.8	513
5	Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2323-2330.	0.8	355
6	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology. <i>JAMA Oncology</i> , 2019, 5, 204.	3.4	317
7	Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1502-1505.	3.3	311
8	Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2803-2808.	3.3	285
9	Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. <i>Journal of Clinical Oncology</i> , 2011, 29, 2357-2363.	0.8	272
10	Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia. <i>Cancer Cell</i> , 2005, 8, 421-432.	7.7	260
11	NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1429-1440.	2.3	249
12	Discovery of common variants associated with low TSH levels and thyroid cancer risk. <i>Nature Genetics</i> , 2012, 44, 319-322.	9.4	208
13	Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. <i>Journal of Medical Genetics</i> , 2004, 41, 161-170.	1.5	181
14	The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. <i>Molecular and Cellular Endocrinology</i> , 2010, 321, 20-28.	1.6	162
15	Genetic Classification of Benign and Malignant Thyroid Follicular Neoplasia Based on a Three-Gene Combination. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2512-2521.	1.8	152
16	H <sup>14</sup> trthle Cell Neoplasms of the Thyroid. <i>Annals of Surgery</i> , 1998, 227, 542-546.	2.1	148
17	Thyroid Carcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1671-1680.	2.3	147
18	Clinical Implications of Genetic Defects in G Proteins: The Molecular Basis of McCune-Albright Syndrome and Albright Hereditary Osteodystrophy. <i>Medicine (United States)</i> , 1996, 75, 171-184.	0.4	144

#	ARTICLE	IF	CITATIONS
19	Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 164-170.	1.8	142
20	Paternal imprinting of $G\hat{1}s$ in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. <i>Biochemical and Biophysical Research Communications</i> , 2002, 296, 67-72.	1.0	141
21	Long-Term Efficacy of Lymph Node Reoperation for Persistent Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2187-2194.	1.8	141
22	A Mouse Model of Albright Hereditary Osteodystrophy Generated by Targeted Disruption of Exon 1 of the <i>Gnas</i> Gene. <i>Endocrinology</i> , 2005, 146, 4697-4709.	1.4	122
23	Hyperthyroid heart disease. <i>Clinical Cardiology</i> , 2000, 23, 402-408.	0.7	118
24	Beyond peroxisome proliferator-activated receptor $\hat{1}^3$ signaling: the multi-facets of the antitumor effect of thiazolidinediones. <i>Endocrine-Related Cancer</i> , 2006, 13, 401-413.	1.6	117
25	A genome-wide association study yields five novel thyroid cancer risk loci. <i>Nature Communications</i> , 2017, 8, 14517.	5.8	117
26	Metastin Receptor Is Overexpressed in Papillary Thyroid Cancer and Activates MAP Kinase in Thyroid Cancer Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2399-2399.	1.8	104
27	Akt Controls Vascular Smooth Muscle Cell Proliferation In Vitro and In Vivo by Delaying G1/S Exit. <i>Circulation Research</i> , 2003, 93, 1059-1065.	2.0	103
28	AKT Activation Promotes Metastasis in a Mouse Model of Follicular Thyroid Carcinoma. <i>Endocrinology</i> , 2005, 146, 4456-4463.	1.4	100
29	Germline <i>SDHx</i> variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. <i>Human Molecular Genetics</i> , 2012, 21, 300-310.	1.4	99
30	Thyocytes Express a Functional Toll-Like Receptor 3: Overexpression Can Be Induced by Viral Infection and Reversed by Phenylmethimazole and Is Associated with Hashimoto's Autoimmune Thyroiditis. <i>Molecular Endocrinology</i> , 2005, 19, 1231-1250.	3.7	97
31	Tall Cell Variant: An Aggressive Form of Papillary Thyroid Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2000, 122, 352-357.	1.1	94
32	The Relationship between Body Mass Index and Thyroid Cancer Pathology Features and Outcomes: A Clinicopathological Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4244-4250.	1.8	94
33	Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules. <i>Thyroid</i> , 2019, 29, 1115-1124.	2.4	93
34	Molecular Diagnosis of Residual and Recurrent Thyroid Cancer by Amplification of Thyroglobulin Messenger Ribonucleic Acid in Peripheral Blood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 4435-4442.	1.8	92
35	Prognostic Importance of Vascular Invasion in Papillary Thyroid Carcinoma. <i>JAMA Otolaryngology</i> , 2000, 126, 309.	1.5	92
36	Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1947-1960.	1.8	92

#	ARTICLE	IF	CITATIONS
37	MicroRNA Signature in Thyroid Fine Needle Aspiration Cytology Applied to Atypia of Undetermined Significance Cases. <i>Thyroid</i> , 2012, 22, 9-16.	2.4	92
38	Anaplastic Thyroid Carcinoma, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1140-1150.	2.3	92
39	Expression of the Sodium Iodide Symporter and Thyroglobulin Genes Are Reduced in Papillary Thyroid Cancer. <i>Modern Pathology</i> , 2001, 14, 289-296.	2.9	91
40	Management of Hypothyroidism and Hyperthyroidism in the Intensive Care Unit. <i>Critical Care Clinics</i> , 2001, 17, 59-74.	1.0	91
41	AKT in Thyroid Tumorigenesis and Progression. <i>Endocrinology</i> , 2007, 148, 942-947.	1.4	88
42	UNUSUAL TYPES OF THYROID NEOPLASMS. <i>Endocrinology and Metabolism Clinics of North America</i> , 1996, 25, 49-68.	1.2	86
43	GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer. <i>Nature Communications</i> , 2020, 11, 3981.	5.8	86
44	Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes microRNA-like tRNA Fragments. <i>Molecular Cancer Research</i> , 2015, 13, 891-901.	1.5	84
45	Dysregulation of the Phosphatidylinositol 3-Kinase Pathway in Thyroid Neoplasia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 375-387.	1.2	82
46	Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. <i>European Journal of Endocrinology</i> , 2004, 151, 779-786.	1.9	80
47	Sudden Enlargement of Local Recurrent Thyroid Tumor after Recombinant Human TSH Administration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5148-5151.	1.8	77
48	2-Amino-N-(4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl) Acetamide (OSU-03012), a Celecoxib Derivative, Directly Targets p21-Activated Kinase. <i>Molecular Pharmacology</i> , 2007, 72, 1124-1131.	1.0	76
49	SRGAP1 Is a Candidate Gene for Papillary Thyroid Carcinoma Susceptibility. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E973-E980.	1.8	74
50	Akt1 contains a functional leucine-rich nuclear export sequence. <i>Biochemical and Biophysical Research Communications</i> , 2005, 332, 167-173.	1.0	72
51	Thyroid nodules and cancer management guidelines: comparisons and controversies. <i>Endocrine-Related Cancer</i> , 2017, 24, R13-R26.	1.6	70
52	KISS-1/G Protein-Coupled Receptor 54 Metastasis Suppressor Pathway Increases Myocyte-Enriched Calcineurin Interacting Protein 1 Expression and Chronically Inhibits Calcineurin Activity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5432-5440.	1.8	68
53	Quantitative Reverse Transcription-Polymerase Chain Reaction of Circulating Thyroglobulin Messenger Ribonucleic Acid for Monitoring Patients with Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 4037-4042.	1.8	67
54	Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy. <i>Otolaryngology - Head and Neck Surgery</i> , 2005, 132, 840-844.	1.1	67

#	ARTICLE	IF	CITATIONS
55	Regulation of actin function by protein kinase A-mediated phosphorylation of Limk1. <i>EMBO Reports</i> , 2009, 10, 599-605.	2.0	67
56	Vascular Endothelial Growth Factor Monoclonal Antibody Inhibits Growth of Anaplastic Thyroid Cancer Xenografts in Nude Mice. <i>Thyroid</i> , 2002, 12, 953-961.	2.4	66
57	Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. <i>Carcinogenesis</i> , 2011, 32, 1467-1473.	1.3	64
58	Cumulative Risk Impact of Five Genetic Variants Associated with Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2013, 23, 1532-1540.	2.4	63
59	Regulation of FRTL-5 Thyroid Cell Growth by Phosphatidylinositol (OH) 3 Kinase-Dependent Akt-Mediated Signaling. <i>Thyroid</i> , 2001, 11, 339-351.	2.4	61
60	Approach to Follow-Up of the Patient With Differentiated Thyroid Cancer and Positive Anti-Thyroglobulin Antibodies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3104-3110.	1.8	59
61	Quantitative Reverse Transcription-PCR Measurement of Thyroglobulin mRNA in Peripheral Blood of Healthy Subjects. <i>Clinical Chemistry</i> , 1999, 45, 785-789.	1.5	57
62	Frequency of Germline PTEN Mutations in Differentiated Thyroid Cancer. <i>Thyroid</i> , 2011, 21, 505-510.	2.4	56
63	Thyroid cancer, recent advances in diagnosis and therapy. <i>International Journal of Cancer</i> , 2021, 149, 984-992.	2.3	56
64	17-Allylamino-17-Demethoxygeldanamycin Activity against Thyroid Cancer Cell Lines Correlates with Heat Shock Protein 90 Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2982-2988.	1.8	55
65	Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2201-2204.	1.8	54
66	A Novel Dual AMPK Activator/mTOR Inhibitor Inhibits Thyroid Cancer Cell Growth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E748-E756.	1.8	49
67	The Role of Radioactive Iodine in Salivary Gland Dysfunction. <i>Ear, Nose and Throat Journal</i> , 2000, 79, 460-468.	0.4	48
68	Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4005-4013.	1.8	47
69	Determination of Galectin-3 Messenger Ribonucleic Acid Overexpression in Papillary Thyroid Cancer by Quantitative Reverse Transcription-Polymerase Chain Reaction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4792-4796.	1.8	46
70	Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. <i>Molecular Carcinogenesis</i> , 2004, 41, 98-107.	1.3	45
71	Subclinical Thyroid Dysfunction—Can There Be a Consensus about the Consensus?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 588-590.	1.8	44
72	Thyroglobulin Liquid Chromatography-Tandem Mass Spectrometry Has a Low Sensitivity for Detecting Structural Disease in Patients with Antithyroglobulin Antibodies. <i>Thyroid</i> , 2017, 27, 74-80.	2.4	44

#	ARTICLE	IF	CITATIONS
73	Active Surveillance Versus Thyroid Surgery for Differentiated Thyroid Cancer: A Systematic Review. <i>Thyroid</i> , 2022, 32, 351-367.	2.4	42
74	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. <i>Head and Neck</i> , 2022, 44, 1277-1300.	0.9	41
75	RCAN1-4 is a thyroid cancer growth and metastasis suppressor. <i>JCI Insight</i> , 2017, 2, e90651.	2.3	40
76	Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. <i>Clinical Cancer Research</i> , 2019, 25, 4749-4760.	3.2	39
77	Assessing thyroid cancer risk using polygenic risk scores. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 5997-6002.	3.3	39
78	Metastatic Dormancy and Progression in Thyroid Cancer: Targeting Cells in the Metastatic Frontier. <i>Thyroid</i> , 2011, 21, 487-492.	2.4	38
79	Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. <i>Endocrine-Related Cancer</i> , 2010, 17, 989-999.	1.6	37
80	Metastatic mechanisms in follicular cell-derived thyroid cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, R307-R319.	1.6	37
81	Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells. <i>Endocrine-Related Cancer</i> , 2012, 19, 291-304.	1.6	36
82	Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells. <i>Experimental Cell Research</i> , 2003, 287, 397-410.	1.2	35
83	Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. <i>Endocrine-Related Cancer</i> , 2012, 19, 29-38.	1.6	35
84	Ultrasound-guided fine-needle aspiration and thyroid disease. <i>Otolaryngology - Head and Neck Surgery</i> , 2000, 123, 700-705.	1.1	34
85	Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters. <i>Thyroid</i> , 2016, 26, 1276-1284.	2.4	32
86	Stromal Platelet-Derived Growth Factor Receptor- $\beta$ Signaling Promotes Breast Cancer Metastasis in the Brain. <i>Cancer Research</i> , 2021, 81, 606-618.	0.4	32
87	AKT: A Potential Target for Thyroid Cancer Therapy. <i>Current Drug Targets Immune, Endocrine and Metabolic Disorders</i> , 2004, 4, 181-185.	1.8	32
88	Follicular Thyroid Cancers Demonstrate Dual Activation of PKA and mTOR as Modeled by Thyroid-Specific Deletion of Prkar1a and Pten in Mice. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E804-E812.	1.8	31
89	Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 121-130.	1.6	30
90	Use of Continuous Glucose Monitor in Critically Ill COVID-19 Patients Requiring Insulin Infusion: An Observational Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4007-e4016.	1.8	30

#	ARTICLE	IF	CITATIONS
91	KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 409-413.	2.3	30
92	Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor- $\alpha$ , CH11 and CYC202. <i>Endocrine-Related Cancer</i> , 2007, 14, 305-315.	1.6	29
93	United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin. <i>Clinical Chemistry</i> , 2017, 63, 1489-1496.	1.5	28
94	Regulator of calcineurin 1 modulates cancer cell migration in vitro. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 517-526.	1.7	27
95	Sudden Enlargement of Local Recurrent Thyroid Tumor after Recombinant Human TSH Administration. , 0, .		27
96	Molecular Detection of Thyroid Cancer: Differentiating "Signal" and "Noise" in Clinical Assays. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 29-32.	1.8	26
97	Development of p21 Activated Kinase-Targeted Multikinase Inhibitors That Inhibit Thyroid Cancer Cell Migration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1314-E1322.	1.8	26
98	Molecular markers of aggressiveness of thyroid cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 361-366.	1.2	24
99	Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring (CGM) in Critically Ill Patients With COVID-19. <i>Endocrine Practice</i> , 2021, 27, 354-361.	1.1	24
100	Combined Use of Perioperative TSH-Stimulated $^{18}\text{F}$ -FDG PET/CT Imaging and Gamma Probe Radioguided Surgery to Localize and Verify Resection of Iodine Scan-Negative Recurrent Thyroid Carcinoma. <i>Laryngoscope</i> , 2008, 118, 2190-2194.	1.1	23
101	In Thyroidectomized Patients with Thyroid Cancer, a Serum Thyrotropin of $30 \pm 1/4$ U/mL After Thyroxine Withdrawal Is Not Always Adequate for Detecting an Elevated Stimulated Serum Thyroglobulin. <i>Thyroid</i> , 2013, 23, 185-193.	2.4	23
102	Genetic Predisposition for Nonmedullary Thyroid Cancer. <i>Hormones and Cancer</i> , 2015, 6, 13-20.	4.9	21
103	Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target. <i>Surgery</i> , 2016, 159, 163-171.	1.0	21
104	Evaluation of adult papillary thyroid carcinomas by comparative genomic hybridization and microsatellite instability analysis. <i>Cancer Genetics and Cytogenetics</i> , 2002, 135, 182-186.	1.0	19
105	Integrating fine-needle aspiration into a daily practice involving thyroid disorders: The Washington Hospital Center approach. <i>Diagnostic Cytopathology</i> , 2002, 27, 120-122.	0.5	19
106	Risk Factors of $^{131}\text{I}$ -Induced Salivary Gland Damage in Thyroid Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4085-4093.	1.8	19
107	Transcriptional targeting of oncogene addiction in medullary thyroid cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	19
108	MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition. <i>Endocrine-Related Cancer</i> , 2019, 26, 699-712.	1.6	19

#	ARTICLE	IF	CITATIONS
109	Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i> -Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. <i>Thyroid</i> , 0, .	2.4	19
110	Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma. , 2000, 1, 173-181.		18
111	Telomere Length and Telomerase Reverse Transcriptase Gene Copy Number in Patients with Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1876-E1880.	1.8	18
112	PTEN Lipid Phosphatase Activity and Proper Subcellular Localization Are Necessary and Sufficient for Down-Regulating AKT Phosphorylation in the Nucleus in Cowden Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2179-E2187.	1.8	18
113	Serum Thyroglobulin Measurement Following Surgery Without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review. <i>Thyroid</i> , 2022, 32, 613-639.	2.4	18
114	Trading One "Dangerous Dogma" for Another? Thyroid Hormone Treatment of the "Euthyroid Sick Syndrome". <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1759-1762.	1.8	17
115	Cytotoxic Activity of 2',2'-Difluorodeoxycytidine (Gemcitabine) in Poorly Differentiated Thyroid Carcinoma Cells. <i>Thyroid</i> , 2000, 10, 865-869.	2.4	17
116	"Thyroid Cancer" Cell Line Misidentification: A Time for Proactive Change. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4226-4227.	1.8	15
117	Apigenin in Combination with Akt Inhibition Significantly Enhances Thyrotropin-Stimulated Radioiodide Accumulation in Thyroid Cells. <i>Thyroid</i> , 2014, 24, 878-887.	2.4	15
118	Tall cell variant: An aggressive form of papillary thyroid carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2000, 122, 352-357.	1.1	14
119	BRAF activates and physically interacts with PAK to regulate cell motility. <i>Endocrine-Related Cancer</i> , 2014, 21, 865-877.	1.6	14
120	Germline compound heterozygous poly-glutamine deletion in <i>USF3</i> may be involved in predisposition to heritable and sporadic epithelial thyroid carcinoma. <i>Human Molecular Genetics</i> , 2016, 26, ddw382.	1.4	14
121	Primary Cell Culture Systems for Human Thyroid Studies. <i>Thyroid</i> , 2016, 26, 1131-1140.	2.4	14
122	Cowden syndrome-associated germline succinate dehydrogenase complex subunit D (SDHD) variants cause PTEN-mediated down-regulation of autophagy in thyroid cancer cells. <i>Human Molecular Genetics</i> , 2017, 26, 1365-1375.	1.4	14
123	Thyroglobulin Messenger Ribonucleic Acid Levels in the Peripheral Blood of Children with Benign and Malignant Thyroid Disease. <i>Pediatric Research</i> , 2001, 49, 429-434.	1.1	13
124	Long-Term Efficacy of Lymph Node Reoperation for Persistent Papillary Thyroid Cancer: 13-Year Follow-Up. <i>Annals of Surgical Oncology</i> , 2019, 26, 1737-1743.	0.7	13
125	Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications. <i>Endocrine</i> , 2020, 70, 24-35.	1.1	13
126	RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. <i>Cancers</i> , 2021, 13, 4950.	1.7	13



#	ARTICLE	IF	CITATIONS
127	Evaluation and Treatment of Post-thyroidectomy Hypocalcemia. , 1998, 8, 34-40.		12
128	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4387-4395.	1.8	12
129	Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer. Thyroid, 2017, 27, 1523-1533.	2.4	12
130	New Horizons: Emerging Therapies and Targets in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e382-e388.	1.8	12
131	High-sensitivity TFA-free LC-MS for profiling histones. Proteomics, 2011, 11, 3326-3334.	1.3	10
132	Neck Ultrasound in Patients with Follicular Thyroid Carcinoma. Hormones and Cancer, 2018, 9, 433-439.	4.9	10
133	Genetic variants in thyroid cancer distant metastases. Endocrine-Related Cancer, 2016, 23, L33-L36.	1.6	9
134	Transcriptome analysis discloses dysregulated genes in normal appearing tumor-adjacent thyroid tissues from patients with papillary thyroid carcinoma. Scientific Reports, 2021, 11, 14126.	1.6	9
135	Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model. Scientific Reports, 2020, 10, 18316.	1.6	8
136	p21-Activated Kinases in Thyroid Cancer. Endocrinology, 2020, 161, .	1.4	8
137	Molecular testing in thyroid cancer diagnosis and management. Best Practice and Research in Clinical Endocrinology and Metabolism, 2023, 37, 101680.	2.2	8
138	Current Therapy for Childhood Thyroid Cancer: Optimal Surgery and the Legacy of King Pyrrhus. Annals of Surgical Oncology, 2003, 10, 4-6.	0.7	7
139	Features of Cytologically Indeterminate Molecularly Benign Nodules Treated With Surgery. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3971-e3980.	1.8	7
140	Frontiers in Thyroid Cancer: December 2009. Thyroid, 2009, 19, 1297-1298.	2.4	6
141	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocrine-Related Cancer, 2020, 27, T27-T39.	1.6	6
142	Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient <sup>131</sup> I Therapy for Differentiated Thyroid Cancer. Thyroid, 2017, 27, 1558-1565.	2.4	5
143	Localization of CaSR Antagonists in CaSR-expressing Medullary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1722-E1729.	1.8	4
144	SDHB Gene Mutation in a Carotid Body Paraganglioma: Case Report and Review of the Paraganglioma Syndromes. Annals of Vascular Surgery, 2014, 28, 1321.e9-1321.e12.	0.4	4

#	ARTICLE	IF	CITATIONS
145	Hodgkin's Disease Treated with Neck Radiation Is Associated with Increased Antibody-Dependent Cellular Cytotoxicity Against Human Extraocular Muscle Cells. <i>Thyroid</i> , 1997, 7, 425-432.	2.4	3
146	A novel PTEN mutation in Cowden syndrome is associated with a mixed degenerative-erosive arthritic process: Potential molecular pathogenic mechanisms. <i>American Journal of Medical Genetics, Part A</i> , 2007, 143A, 1522-1527.	0.7	3
147	Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3268-3277.	1.8	3
148	Compensation, Productivity, and Other Demographics of Academic Divisions of Endocrinology, Diabetes, and Metabolism. <i>Journal of the Endocrine Society</i> , 2019, 3, 1485-1502.	0.1	3
149	Resistance to TSH in Patients with Normal TSH Receptors—Where Do We Turn When “Sutton’s Law” Proves False?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3930-3932.	1.8	2
150	Development of a calcium-sensing receptor molecular imaging agent. <i>Surgery</i> , 2013, 154, 1378-1384.	1.0	2
151	Diagnostic Molecular Markers in Thyroid Cancer. , 2004, 122, 295-316.		2
152	Chapter 2 Molecular markers of thyroid nodules. <i>Advances in Molecular and Cellular Endocrinology</i> , 2006, 4, 19-34.	0.1	1
153	Do tumor characteristics predict risk of malignancy in thyroid nodules with indeterminate cytology?. <i>Nature Reviews Endocrinology</i> , 2009, 5, 140-141.	4.3	1
154	Prevalence of cancer and the benign call rate of a firm gene classifier in 18 F-fluorodeoxyglucose positron emission tomography positive cytologically indeterminate thyroid nodules. <i>Cancer Medicine</i> , 2021, 10, 1084-1090.	1.3	1
155	Molecular Pathogenesis of Thyroid Neoplasia. , 2021, , 181-185.e5.		1
156	Recombinant Human Thyrotropin. , 2006, , 103-113.		1
157	Akt signaling in thyroid neoplasia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2004, 11, 197-204.	0.6	0
158	Emerging Therapies for Thyroid Cancer. , 2006, , 423-428.		0
159	Can ultrasound and clinical features be used to predict thyroid cancer in solitary nodules and multinodular goiter?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 334-335.	2.9	0
160	Regulation of actin function by protein kinase A-mediated phosphorylation of Limk1. <i>EMBO Reports</i> , 2009, 10, 1066-1066.	2.0	0
161	Reply to A. Machens et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e535-e536.	0.8	0
162	Linking oncogenes to invasion in thyroid cancer. <i>Cell Cycle</i> , 2011, 10, 741-740.	1.3	0

#	ARTICLE	IF	CITATIONS
163	Diagnosis of Recurrent Thyroid Cancer in Patients with Anti-thyroglobulin Antibodies. , 2016, , 449-454.		0
164	Building on strength. Endocrine-Related Cancer, 2021, 28, E1-E2.	1.6	0
165	Radioiodine: 80 years and counting; the past, present, and future. Endocrine-Related Cancer, 2021, 28, E3-E4.	1.6	0
166	Miscellaneous and Unusual Types of Thyroid Tumors. , 2006, , 553-569.		0
167	Alternative Options and Future Directions for Thyroid Cancer Therapy. , 2006, , 665-670.		0
168	Diagnosis of Recurrent Thyroid Cancer in Patients with Antithyroglobulin Antibodies. , 2006, , 305-308.		0
169	Future Directions for Advanced Thyroid Cancer Therapy. , 2016, , 991-999.		0
170	Miscellaneous and Unusual Tumors of the Thyroid Gland. , 2016, , 825-843.		0